RxDoctor Payments Data

Lung Tan

Podiatrist · Saint Joseph, MONPI 1205862778

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 100.0% of the total across 242 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 32 manufacturers, the largest accounting for just 20.2% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2019 at $1,894 and has fallen 58.1% since, to $794 in 2025.

$6,430in general payments, 2019–2025

Across 242 payments — averaging $26.57 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Smith+Nephew$1K
  • Mimedx Group, Inc.$1K
  • Stryker$880
  • Koya Medical, Inc.$543
  • Amgen$498
  • Organogenesis Inc.$339
  • plus $2K from 26 others

What the payments were for

  • Food & beverage$6,430100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$6,430 in reported general payments places this provider in the 85th percentile of 105 podiatrist providers in Missouri.

See all podiatrist providers in Missouri

Medicare billing

Part B allowed, 2024
$183,106
Medicare patients
1,086
Services billed
4,608

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
SantylCollagenase Clostridium Hist.33$19,352
Lidocaine19$10,991
Ammonium Lactate346$7,261
Pregabalin352$6,419
Diclofenac Sodium41$1,823
Gabapentin88$1,602
CiclopiroxCiclopirox Olamine97$1,359
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen73$870
Diclofenac Sodium ErDiclofenac Sodium18$819
Clindamycin Hcl27$473
Doxycycline Hyclate21$456
Meloxicam82$273
Prednisone39$204
Terbinafine Hcl13$195
Amoxicillin-Clavulanate PotassAmoxicillin/Potassium Clav22$185

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Smith+NephewSantyl$1,298$19,35233 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 105 podiatrist providers in Missouri.

Other podiatrist in Saint Joseph

See the full list for Missouri

Where these figures come from

Is this you, or does something look wrong? →